Amgen Inc.

Valuation Analysis

About the Company

Amgen Inc. en bref

Amgen Inc. (AMGN) is currently trading at 294,62 € with a market capitalization of 159,0 Md €. The trailing P/E ratio stands at 23.49x, with a forward P/E of 14.38x. The 52-week range spans from 233,73 € to 341,47 €; the current price is 13.7% below the yearly high. Year-over-year revenue growth stands at +5.8%. The net profit margin stands at 20.96%.

💰 Dividende

Amgen Inc. pays an annual dividend of 8,80 € per share, representing a yield of 2.99%. The payout ratio stands at 67.22%.

📊 Avis des analystes

30 analystes évaluent Amgen Inc. (AMGN) au consensus : Acheter. L'objectif de cours moyen est de 307,85 €, soit un potentiel de +4.49% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 174,54 € à 372,63 €.

Amgen Inc. : la thèse d'investissement en détail

Amgen Inc. (AMGN) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 71.44%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 101.32% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 20.96%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

The debt-to-equity ratio of 623.75% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

À surveiller

• The forward P/E of 14.38x is meaningfully below the trailing 23.49x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Amgen Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.